NASDAQ$ITOS
iTeos Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
ITOS Q1 2024 — $12.6M revenue, 35.00 EPS
Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient d. iTeos Therapeutics Inc reported Q1 2024 results. Diluted EPS came in at $35.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $12.6M.
- Diluted EPS: $35.00.
- Operating income: $47K.
Headline financials
Revenue & EPS history
iTeos Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q1 2024
+0.8%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+11.8%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+39.6%
Q1 2024
Best reaction
-11.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.2% | +0.0% | — | |
| Q1 2025 | -0.4% | +13.3% | +52.2% | |
| Q4 2024 | -3.7% | -6.4% | -11.4% | |
| Q3 2024 | -5.9% | -12.4% | -15.6% | |
| Q2 2024 | -3.4% | +1.4% | -3.1% | |
| Q1 2024 | +39.6% | +47.5% | +36.9% | |
| Q4 2023 | +5.1% | +8.0% | +12.0% | |
| Q3 2023 | -3.1% | — | — | |
| Q2 2023 | -2.6% | — | — | |
| Q1 2023 | -0.8% | — | — | |
| Q4 2022 | -7.7% | — | — | |
| Q3 2022 | +16.2% | — | — | |
| Q2 2022 | -9.4% | — | — | |
| Q1 2022 | +3.2% | — | — | |
| Q4 2021 | -3.6% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | -1.5% | — | — | |
| Q1 2021 | +8.5% | — | — | |
| Q4 2020 | -11.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro